Polymorphism of coagulation factor genes in patients with type 2 diabetes mellitus and chronic heart failure with retained ejection fraction

BACKGROUND. Patients with type 2 diabetes mellitus (DM2) have disorders of cellular and plasma hemostasis independent of the level of glycemia, increased platelet activation, combined with microvascular angiopathy. The study of the role of genetic markers of hemostasis disorders in the formation and progression of chronic heart failure (CHF) in patients with type 2 diabetes will allow for prevention, possibly optimize treatment and improve prognosis.

AIM. To reveal polymorphisms of genes of the hemostasis system in patients with type 2 diabetes mellitus and chronic heart failure with preserved ejection fraction.

MATERIALS AND METHODS. The frequency of coagulation factor genetic polymorphisms was studied in patients with CHF-pEF and DM2 (52 people), CHF with reduced ejection fraction (CHF-rEF) and DM2 (49) and healthy volunteers (66), mean age 69.9±10.1 years old. DNA was isolated from venous blood according to the method of the manufacturer. Genetic polymorphisms were determined by real-time polymerase chain reaction.

RESULTS. The frequencies of polymorphisms rs1799963 and rs6025 of the genes of blood coagulation factors F2 (prothrombin) and F5 (factor V of blood coagulation) in all three groups were insignificant and comparable in magnitude. In patients with CHF and DM2, the frequencies of the rs6046 polymorphism of the factor F7 gene in the heterozygous form were slightly higher (by 2.6 and 1.7 times, respectively) than in the control group, but the result was not statistically significant. The CHF-pEF and CHF-rEF groups differ in the frequencies of F13 (rs5985) and fibrinogen (rs1800790) genetic polymorphisms, but are more common in patients with CHF-rEF and DM2.

CONCLUSION. Based on the results of the study, it follows that the groups of CHF-pEF and CHF-rEF differ significantly in the frequencies of polymorphisms of the studied genes, both among themselves and with the control group. The highest frequency of polymorphisms of genes, the products of which are involved in the coagulation and cellular components of hemostasis, is observed in the group of patients with DM2 and CHF-rEF.

1. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-1385. doi: https://doi.org/10.1093/eurheartj/ehn153

2. Kindermann M, Bohm M. Sweet hearts die earlier – lessons from CHARM. Eur Heart J. 2008;29(11):1342-1343. doi: https://doi.org/10.1093/eurheartj/ehn203

3. Kubisz P, Stančiaková L, Staško J, et al. Endothelial and platelet markers in diabetes mellitus type 2. World J Diabetes. 2015;6(3):423-431. doi: https://doi.org/10.4239/wjd.v6.i3.423.

4. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus. J Clin Invest. 1979;63(3):485-493. doi: https://doi.org/10.1172/JCI109326

5. Ceriello A. Coagulation activation in diabetes mellitus: the role or hyperglycaemia and therapeutic prospects. Diabetologia. 1993;36(11):1119-1125. doi: https://doi.org/10.1007/BF00401055

6. Skibowska A, Raszeja-Specht A, Szutowicz A. Platelet function and acetylcoenzyme a metabolism in type 1 diabetes mellitus. Clin Chem Lab Med. 2003;41(9):1136-1143. doi: https://doi.org/10.1515/CCLM.2003.176

7. Kajita K, Ishizuka T, Miura A, et al. Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control. Platelets. 2001;12(6):343-351. doi: https://doi.org/10.1080/09537100120078386

8. Jung RG, Motazedian P, Ramirez FD, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb J. 2018;16(1):12. doi: https://doi.org/10.1186/s12959-018-0166-4

9. Ašić A, Salazar R, Storm N, et al. Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. Croat Med J. 2019;60(3):212-220. doi: https://doi.org/10.3325/cmj.2019.60.212

10. Shafey M, Anderson J, Scarvelis D, et al. Factor XIII Val34Leu variant and the risk of myocardial infarction. Thromb Haemost. 2007;97(04):635-641. doi: https://doi.org/10.1160/TH06-09-0517

11. Vokó Z, Bereczky Z, Katona É, et al. Factor XIII Val34Leu variant protects against coronary artery disease. Thromb Haemost. 2007;97(03):458-463. doi: https://doi.org/10.1160/TH06-11-0676

12. Wells PS, Anderson JL, Scarvelis DK, et al. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164(2):101-109. doi: https://doi.org/10.1093/aje/kwj179

13. Albert MA, Pare G, Morris A, et al. Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: data from the Women’s Genome Health Study. Am Heart J. 2009;157(4):777-783. doi: https://doi.org/10.1016/j.ahj.2008.12.012

14. Mihaleva I, Mincheva M, Hristova-Savova M, et al. Screening for Genetic Variants Suggests β-fibrinogen -455 G/A Genotype as a Contributor to Cardiovascular Complications in Type 2 Diabetes Mellitus. 2020; PREPRINT (Version 1) available at Research Square. [Digital]. doi: https://doi.org/10.21203/rs.3.rs-51215/v1

15. Leander K, Wiman B, Hallqvist J, et al. PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction. Thromb Haemost. 2003;89(06):1064-1071. doi: https://doi.org/10.1055/s-0037-1613409

16. Miri S, Sheikhha MH, Dastgheib SA, et al. Association of ACE I/D and PAI-1 4G/5G polymorphisms with susceptibility to type 2 diabetes mellitus. J Diabetes Metab Disord. 2021;20(2):1191-1197. doi: https://doi.org/10.1007/s40200-021-00839-7

17. Rath D, Schaeffeler E, Winter S, et al. GPla Polymorphisms Are Associated with Outcomes in Patients at High Cardiovascular Risk. Front Cardiovasc Med. 2017;4(2):1191-1197. doi: https://doi.org/10.3389/fcvm.2017.00052

18. Khatami M, Heidari MM. Common rs5918 (PlA1/A2) polymorphism in the ITGB3 gene and risk of coronary artery disease. Arch Med Sci – Atheroscler Dis. 2016;1(1):9-15. doi: https://doi.org/10.5114/amsad.2016.59587

19. Nikolajević-Starčević J, Petrovič MG, Petrovič D. A1/A2 polymorphism of the glycoprotein IIIa gene and diabetic retinopathy in Caucasians with type 2 diabetes. Clin Experiment Ophthalmol. 2011;39(7):665-672. doi: https://doi.org/10.1111/j.1442-9071.2011.02520.x